Navigation Links
Cortex Area Thinner in Youth with Alzheimers-Related Gene

BETHESDA, Md., April 23, 2007--A part of the brain first affected by Alzheimers disease (http://www.nia.nih.gov/Alzheimers/) is thinner in youth with a risk gene for the disorder, a brain imaging study by researchers at the National Institute of Mental Health (NIMH), one of the National Institutes of Health (NIH), has found. A thinner entorhinal cortex, a structure in the lower middle part of the brains outer mantle, may render these youth more susceptible to degenerative changes and mental decline later in life, propose Drs. Philip Shaw, Judith Rapoport, Jay Giedd, and NIMH and McGill University colleagues. They report on how variation in the gene for apoliproprotein (ApoE), which plays a critical role in repair of brain cells, affects development of this learning and memory hub in the June, 2007 Lancet Neurology.

People with the Alzheimers-related variant of the ApoE gene might not be able to sustain much aging-related tissue loss in the entorhinal cortex before they cross a critical threshold, explained Shaw. But the early thinning appears to be a harmless genetic variation rather than a disease-related change, as it did not affect youths intellectual ability. Only long-term brain imaging studies of healthy aging adults will confirm whether this anatomical signature detectible in childhood predisposes for Alzheimers.

It was already known that adults destined to develop Alzheimers disease tend to have a smaller and less active entorhinal cortex (http://www.nia.nih.gov/Alzheimers/ResearchInformation/NewsReleases/Archives/PR2000/PR20000329MRI.htm). This structure is the first to shrink in volume and to develop the neurofibrillary tangles (




Page: 1 2 3 4

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cortex Area Thinner Youth with Alzheimers Related Gene
(Date:11/25/2008)... Proteolix, Inc., a,leader in the...hat target,protein degradation pathways in cancer...ta from two ongoing Phase 2 clinical trials of car... the upcoming 50th Annual Meeting of the,American...first in a new class,of specific proteasome inhib...
(Date:11/25/2008)...ial to Assess Survival of Patients Receiving Litx ... Hepatocellular Carcinoma , , BELLEVUE, Was...y, Inc. (LSO) today announced the completion of en...ht Infusion Therapy(TM) (Litx(TM)) as a treatment ...lso known as hepatoma or primary liver cancer. , ...
(Date:11/24/2008)...e/ -- Domino,s Pizza (NYSE: DPZ ), the,recogniz...o raise dough for,the kids of St. Jude Children,s... and Giving campaign. Domino,s customers will have...urchase to benefit the children of St. Jude.,Dona...when ordering online at, www.dominos.com . The ca...
(Date:11/24/2008)...dership and long-term commitment to hepatitis rese...ire-FirstCall/ -- Schering-Plough Corporation (NYS...eprevir, its lead investigational oral hepatitis C...ment. The company believes boceprevir has the pot...otease inhibitor for treating chronic hepatitis C....
Breaking Medicine Technology:Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9United BioSource Acquires Caro Research Leader in Simulation Modeling 620 1United BioSource Acquires Caro Research Leader in Simulation Modeling 620 2CEL SCI CEO to Present Tomorrow at the Biotech Pharma Healthcare On Line Forum 283 1CEL SCI CEO to Present Tomorrow at the Biotech Pharma Healthcare On Line Forum 283 2The Nutrition Conscious Take a Bite Out of Fast Food 1394 1The Nutrition Conscious Take a Bite Out of Fast Food 1394 2The Nutrition Conscious Take a Bite Out of Fast Food 1394 3The Nutrition Conscious Take a Bite Out of Fast Food 1394 4Metropolitan Hosts Informational Meetings in Nassau County 1391 1
... Fail to Demonstrate Meaningful Placebo Adjusted W...W YORK, July 09, 2007 /PRNewswire-FirstCall/ -- Ma...lts of the company,s two,Phase 2a clinical trials ...andomized, double-blind, placebo-controlled studie...besity, demonstrated no,statistically or clinicall...
...ction of rHuPH20 with Humira Estimated to Increase...lity from 64% to 100%,-, SAN DIEGO, July 09, 2007 ...nc. , a biopharmaceutical company developing and,c...nounced that,final results of the Enhanze(TM) Tech...ption and bioavailability of a,representative comm...
Other Medicine Technology:Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 3Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5
(Date:12/2/2008)...f., Dec. 2 Internationally recogni...an invited speaker for this,year,s annual meeting... (Photo: http://www.newscom.com/cgi-bin/prnh...y is minimally invasive (or ,Goldilocks,) anesthes...d ,PK 101, minimally invasive,anesthesia for mini...
(Date:12/2/2008)...ica, Dec. 2 The Healthcare group a...ost.com ) is pleased to announce that,it will be ...dustry in,sub-Saharan Africa on Friday 12 Decembe...www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , ...althcare services is a,relatively novel concept i...
(Date:12/2/2008)... For many families, the problem with the holi...vides insight into how caregivers of aging parents...der care experience. , Sa...amilies the stress of the holiday season is family...er care expert Esther Koch , founder of Encore M...
(Date:12/2/2008)... Orion Health announces that the SouthEast Al..., Alaska, has selected the Rhapsody™ Integra...h record, radiology, pharmacy, laboratory and busi... plans to extend connectivity to statewide systems... registry) and AKAIMS (an MIS and clinical documen...
Breaking Medicine News(10 mins):Health News:The Future of Financing Health Services in Africa 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3
...ished in The Lancet on adolescent health, the curr...ompared to their parents.// The infections of the ...en way to venereal diseases, drinking, smoking, ob...er lining to this issue is that these conditions c...
...eart disease medicine of Sanofi-Aventis will be ma... the pharma company on Tuesday.// As per the offe...approved plans to buy or make imitated version of ...drug firm states that indigenous making of the hea...
...e the latest trend which is making waves in the he...arn and develop their skills to make sure the eval... of patients. More than 170 physician performanc...a, heart failure and emergency care through the Ph...
... aerated drink manufacturers Pepsico and Coca Cola...// The Ganguly report had deduced that pesticide r...Pepsico and Coca cola should be furnished within s...a civil society group had filed a public interest ...
Other Medicine News:
...ased, 2-8-channel system for measuring bioelectric...optic nerve. The basic set comprises: computer dev...ioelectrical amplifier, electrodes and checkerboar...o install. The recorded curves are displayed on a ...
A sophisticated research tool that allows to see the fundus picture of the area which is being stimulated. Besides it also includes the refractive pupil camera enabling the examiner to switch between
5 mm
Cannula and irrigation extension. Overall Length 150 mm (6.25"). Light Curve.
Medicine Products: